Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2017 by M.D. Anderson Cancer Center
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01365169
First received: June 1, 2011
Last updated: April 11, 2017
Last verified: April 2017
  Purpose

Objectives:

To explore the feasibility and acceptability in diverse samples of cancer patients of wireless collection and transmission of data for transfer into the open-source cyberinfrastructure (CI) called CYCORE


Condition Intervention
Advanced Cancers
Colorectal Cancer
Head And Neck Cancer
Cancer Survivors
Device: Smart phone
Device: Accelerometers
Device: Blood Pressure Monitor
Other: Telephone Surveys
Other: Home Visit
Device: Home Health Hub and Modem
Device: Carbon Monoxide (CO) Monitor
Device: Heat Rate Monitor
Device: Global Positioning System (GPS) Device
Other: Surveys
Device: Weight Scale
Device: Fitbit Monitor
Behavioral: At-Home Exercise Program
Behavioral: Physical Fitness Tests
Behavioral: Questionnaires
Behavioral: Lean Body Mass Assessment

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: CYCORE: Cyberinfrastructure for Comparative Effectiveness Research - Feasibility Trial

Resource links provided by NLM:


Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Study Completion as Evidenced by Completion of Final Assessment [ Time Frame: Participant survey data collection over 10 days, study data collection one year. ]
    Primary feasibility endpoint is study completion represented as number of participants who complete study final assessment.


Estimated Enrollment: 290
Actual Study Start Date: June 2011
Estimated Study Completion Date: June 2019
Estimated Primary Completion Date: June 2019 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Exercise Adherence Arm (Arm 1) Device: Smart phone
Answer questions sent by the phone . Some participants will video-record swallowing exercises or device usage.
Device: Accelerometers
These devices are worn on a belt around the waist, and record activity.
Device: Blood Pressure Monitor
This device is used at home to measure blood pressure and pulse rate.
Other: Telephone Surveys
On days 1, 3, and 6 of each 5-day sensor usage period, study personnel will call participants to ascertain functionality, acceptability, and overall satisfaction regarding use of sensing devices.
Other: Home Visit
For the first 10 patients enrolled in the trial, a home visit to be made on day 2, to ascertain if there were any problems related to home set-up.
Device: Home Health Hub and Modem
These devices collect data from other home devices, and send this data (over the internet) to study researchers.
Device: Heat Rate Monitor
This device is worn on a chest strap, and measures heart rate.
Device: Global Positioning System (GPS) Device
This device describes location on a map, but not location within a building.
Other Name: GPS
Other: Surveys
After training about each device, completion of a survey about that training.
Dehydration Risk Arm (Arm 2) Device: Smart phone
Answer questions sent by the phone . Some participants will video-record swallowing exercises or device usage.
Device: Accelerometers
These devices are worn on a belt around the waist, and record activity.
Device: Blood Pressure Monitor
This device is used at home to measure blood pressure and pulse rate.
Other: Telephone Surveys
On days 1, 3, and 6 of each 5-day sensor usage period, study personnel will call participants to ascertain functionality, acceptability, and overall satisfaction regarding use of sensing devices.
Other: Home Visit
For the first 10 patients enrolled in the trial, a home visit to be made on day 2, to ascertain if there were any problems related to home set-up.
Device: Home Health Hub and Modem
These devices collect data from other home devices, and send this data (over the internet) to study researchers.
Other: Surveys
After training about each device, completion of a survey about that training.
Device: Weight Scale
Weight scale will monitor weight.
Swallowing Exercise Adherence Arm (Arm 3) Device: Smart phone
Answer questions sent by the phone . Some participants will video-record swallowing exercises or device usage.
Other: Telephone Surveys
On days 1, 3, and 6 of each 5-day sensor usage period, study personnel will call participants to ascertain functionality, acceptability, and overall satisfaction regarding use of sensing devices.
Other: Home Visit
For the first 10 patients enrolled in the trial, a home visit to be made on day 2, to ascertain if there were any problems related to home set-up.
Device: Home Health Hub and Modem
These devices collect data from other home devices, and send this data (over the internet) to study researchers.
Other: Surveys
After training about each device, completion of a survey about that training.
Smoking Cessation Adherence Arm (Arm 4) Device: Smart phone
Answer questions sent by the phone . Some participants will video-record swallowing exercises or device usage.
Other: Telephone Surveys
On days 1, 3, and 6 of each 5-day sensor usage period, study personnel will call participants to ascertain functionality, acceptability, and overall satisfaction regarding use of sensing devices.
Other: Home Visit
For the first 10 patients enrolled in the trial, a home visit to be made on day 2, to ascertain if there were any problems related to home set-up.
Device: Home Health Hub and Modem
These devices collect data from other home devices, and send this data (over the internet) to study researchers.
Device: Carbon Monoxide (CO) Monitor
This device captures the CO level expelled in one breath.
Other: Surveys
After training about each device, completion of a survey about that training.
Pre-Pilot Device: Smart phone
Answer questions sent by the phone . Some participants will video-record swallowing exercises or device usage.
Device: Accelerometers
These devices are worn on a belt around the waist, and record activity.
Device: Blood Pressure Monitor
This device is used at home to measure blood pressure and pulse rate.
Other: Telephone Surveys
On days 1, 3, and 6 of each 5-day sensor usage period, study personnel will call participants to ascertain functionality, acceptability, and overall satisfaction regarding use of sensing devices.
Other: Home Visit
For the first 10 patients enrolled in the trial, a home visit to be made on day 2, to ascertain if there were any problems related to home set-up.
Device: Home Health Hub and Modem
These devices collect data from other home devices, and send this data (over the internet) to study researchers.
Device: Carbon Monoxide (CO) Monitor
This device captures the CO level expelled in one breath.
Device: Heat Rate Monitor
This device is worn on a chest strap, and measures heart rate.
Device: Global Positioning System (GPS) Device
This device describes location on a map, but not location within a building.
Other Name: GPS
Other: Surveys
After training about each device, completion of a survey about that training.
Device: Weight Scale
Weight scale will monitor weight.
Pancreas Cancer Group Device: Accelerometers
These devices are worn on a belt around the waist, and record activity.
Device: Weight Scale
Weight scale will monitor weight.
Device: Fitbit Monitor
Participants wear a Fitbit monitor on wrist all day and night starting from the day they receive the monitor (up to 4 weeks before surgery) until final study visit (3-7 months after surgery).
Behavioral: At-Home Exercise Program
Participants participate in a walking program and strengthening exercise program at home guided by a rehabilitation specialist.
Behavioral: Physical Fitness Tests
Participants strength checked using a hand-held grip test. Walking speed will be checked with a 6-minute walking test. Tests to check your balance, walking speed, and ability to stand from a seated position also performed. Tests to be done 3 times: (1) before surgery, (2) 4-7 weeks after surgery, and (3) 3-7 months after surgery.
Behavioral: Questionnaires

Questionnaires completed about physical ability, health, and quality-of-life 3 times: (1) before pancreatic surgery, (2) 4-7 weeks after surgery, and (3) 3-7 months after surgery. About 1 week after participant leaves the hospital for surgery, participant again completes the physical ability and quality-of-life questionnaires. Participant to re-take the quality-of-life questionnaire 7-10 days after each of the 4 time-points noted above. This will take about 7-10 minutes each time.

Participant completes a questionnaire about the usefulness of the devices used at home. Questionnaires completed 2 times: the first will be 1 week after starting using the weight scale and the second will be 3-7 months after surgery.

Other Name: Surveys
Behavioral: Lean Body Mass Assessment
If computerized tomography (CT) scans are performed as part of routine medical care, the study staff will look at 3 of those scans to estimate participant's lean body mass. If available, the study staff will also look at CT scans at 3 time points: before surgery, at about 4-7 weeks after discharge from hospital for that surgery, and 3-7 months after surgery.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
MD Anderson Cancer Center patients from Head and Neck clinics, Colorectal clinics, and Smoking Cessation groups.
Criteria

Inclusion Criteria:

  1. Diagnosis of any stage I - IV colorectal cancer or recurrent colorectal cancer (Arm 1)
  2. Able to speak, read, and write in English (Pre-pilot phase, Arms 1-4)
  3. Able to provide informed consent (Pre-pilot phase, Arms 1-4, PCS study)
  4. Lives in the Houston area (Harris county or a contiguous county) (Pre-pilot phase)
  5. Age 18 years or older (Pre-pilot phase, Arms 1-4)
  6. ECOG status of 0 - 2, or self reports being up and about more than 50% of waking hours and able to provide self care (Arm 1)
  7. Diagnosis of any of the following cancers: stage 1-4b oropharyngeal, hypopharyngeal, nasopharyngeal, salivary gland or oral cavity; stage 3-4b laryngeal; any unknown primary head and neck cancer with cervical metastasis that will be addressed with treatment to bilateral necks and mucosa; or other head and neck cancers medically approved by one of our Radiation Oncology collaborating MDs (Arms 2 and 3)
  8. History of any cancer, other than non-melanoma skin cancer (Arm 4)
  9. Admitted to being a current smoker or recent quitter upon admission to MDACC (Arm 4)
  10. Has a valid home address and functioning home telephone number (Arm 4)
  11. Lives in the Houston or surrounding area, or resides in this same area during the time period that coincides with this study (Arms 1-4)
  12. Patients who will undergo curative pancreatectomy for pancreatic adenocarcinoma, pancreatic neuroendocrine tumors, or pancreatic cysts (malignant or benign) (PCS study)
  13. Fluent in English (PCS study)
  14. Must have telephone access and agree to engage with research personnel using telephone (PCS study)

Exclusion Criteria:

  1. Major surgery in the past 8 weeks (Arms 1 and 4)
  2. Self-reports hypertension that is not being monitored by a physician and is not being managed with either medication, observation, or lifestyle change (Pre-pilot phase, Arms 1-3)
  3. Overt cognitive difficulty demonstrated by not being clearly oriented to time or person or place (Arms 1-4)
  4. Orthopedic, neurologic, or musculoskeletal disability that would interfere with the functional task of standing on a weight scale (Pre-pilot phase, Arm 2)
  5. Not currently receiving radiation treatment for a cancer listed in the Arm-specific inclusion criteria (Arms 2 and 3)
  6. Zubrod Performance Status >2, or self reports either not being up and about more than 50% of waking hours or unable to provide self care (Arms 2 and 3)
  7. Currently receiving treatment for a cancer other than those listed in the Arm-specific inclusion criteria (exception: the study does not exclude those receiving treatment for non-melanoma skin cancer) (Arms 2 and 3)
  8. History of current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g. dysphagia due to underlying neurogenic disorder) (Arm 3 only)
  9. Active substance use disorder (diagnosed or strongly suspected) (Arm 4)
  10. Currently enrolled in protocol 2014-0712 (PCS study)
  11. No home access to internet (PCS study)
  12. No home WiFi connection (PCS study)
  13. Presents with high risk for non-therapeutic resection related to cancer diagnosis (PCS study)
  14. During clinician's pre-surgical evaluation, presents with high risk for non-therapeutic resection related to cancer diagnosis (PCS study)
  15. Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease (New York Heart Association functional class III or IV) (PCS study)
  16. Recent fracture or acute musculoskeletal injury that precludes the ability to fully bear weight on all 4 limbs in order to participate in an exercise intervention (PCS study)
  17. Poorly-controlled pain with a self-reported pain score of ≥ 7/10 at the time of enrollment (PCS study)
  18. Myopathic or rheumatologic disease that impacts physical function (PCS study)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01365169

Contacts
Contact: Susan Peterson, PHD, MPH 713-792-8267

Locations
United States, Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Investigators
Principal Investigator: Susan Peterson, PHD, MPH M.D. Anderson Cancer Center
  More Information

Additional Information:
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT01365169     History of Changes
Other Study ID Numbers: 2010-0955
NCI-2014-02468 ( Registry Identifier: NCI CTRP )
RC2CA148263 ( US NIH Grant/Contract Award Number )
R01CA177996 ( US NIH Grant/Contract Award Number )
Study First Received: June 1, 2011
Last Updated: April 11, 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by M.D. Anderson Cancer Center:
Carbon Monoxide
Cyberinfrastructure
CI
CYCORE
Quality of Life
QOL
Head and Neck
H&N
CO
Colorectal Cancer
Oropharyngeal Cancer
Laryngeal Cancer
Hypopharyngeal Cancer
Nasopharyngeal Cancer
Smoker
Recent Smoking Cessation

Additional relevant MeSH terms:
Carbon Monoxide
Colorectal Neoplasms
Head and Neck Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Gasotransmitters
Neurotransmitter Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 24, 2017